Amit Sachdev - 01 Feb 2022 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
EVP, Chief Patient Officer
Signature
/s/ Sabrina Yohai, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
01 Feb 2022
Net transactions value
$0
Form type
4
Filing time
03 Feb 2022, 15:24:11 UTC
Previous filing
16 Nov 2021
Next filing
14 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Award $0 +9,800 +31% $0.000000 41,728 01 Feb 2022 Direct F1
transaction VRTX Common Stock Award $0 +11,628 +28% $0.000000 53,356 01 Feb 2022 Direct F2
transaction VRTX Common Stock Award $0 +8,210 +15% $0.000000 61,566 01 Feb 2022 Direct F3
holding VRTX Common Stock 882 01 Feb 2022 401(k)
holding VRTX Common Stock 15,573 01 Feb 2022 Held in Trust
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2019 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest on 02/24/2022.
F2 Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2021 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest in installments beginning on 02/17/2022.
F3 Restricted stock unit award that vests in installments beginning on 02/24/2023.

Remarks:

Exhibit 24 - Power of Attorney